Bipolar Disorder – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of bipolar disorder (BPD) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan). We report the prevalence of BPD for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.
Clarivate Epidemiology’s BPD forecast will answer the following questions:
- How will improvements in survival change the number of people living with a diagnosis of BPD?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of BPD over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Clarivate Epidemiology provides at least ten years of forecast data for the following BPD patient populations:
- Total lifetime prevalent cases of BPD.
- Total lifetime prevalent cases of BPD I by manic comorbidity status.
- Total lifetime prevalent cases by generalized anxiety comorbidity status.
- Total lifetime prevalent cases by major depressive episode comorbidity status.
- Total incident cases.
- Lifetime DALYs gained.
- Diagnosed lifetime prevalent cases.
- Diagnosed drug-treated lifetime prevalent cases.
Note: Coverage may vary by country and region.
Table of contents
- Bipolar Disorder - Epidemiology - Mature Markets
- Introduction
- Key Findings
- Key Updates
- Total Prevalence of Bipolar Disorder per 1,000 People Aged 20+ in 2021 and 2041ttttttttttttttt
- Relative Sizes of the Factors Contributing to the Trend in Prevalent Cases of Bipolar Disorder over the Next 20 Yearsttttttttt
- Number of Additional Total Prevalent Cases of Bipolar Disorder Incurred Over 2021-2041 in the Countries Under Studyttttttttt
- Analysis of the Total Prevalent Cases of Bipolar Disorder in 2021 by Subtypettttttttt
- Key Findings
- Epidemiology Data
- Methods
- Total Lifetime Prevalence
- Comorbid Depression
- Comorbid Generalized Anxiety Disorder
- Comorbid Bipolar Mania
- Total Lifetime Incident Cases
- Diagnosed Prevalence
- Drug-Treated Prevalence
- Lifetime DALYs Gained
- Subthreshold Bipolar Disorder
- Reference Materials
- Literature Review
- Studies Included in the Analysis of Bipolar Disorder
- Studies Excluded from the Analysis of Bipolar Disorder
- Risk/Protective Factors
- Risk/Protective Factors for Bipolar Disorder
- Glossary
- Literature Review
- Introduction
Jagriti Prasad, M.P.H., is an associate epidemiologist at Clarivate. Prior to joining the company, she worked on a research project exploring trends in a rare cancer and its subtype using data spanning 44 years in the largest cancer registry of northern England (NRYPMDR). She obtained her M.P.H. from Newcastle University in the United Kingdom and her B.D.S. from Manipal University in India.
Mudasir Khan, M.P.H., Manager, Epidemiology. Before joining Clarivate, Mr. Khan worked as a team lead at IKS Health, an organization that works on patient-level healthcare data management. His areas of expertise at the Clarivate epi team are oncology and psychiatry. He holds a master’s degree in public health from the Tata Institute of Social Sciences in Mumbai.